RKDA inks deal with Roosevelt to become a new entity, Roosevelt Resources, with Roosevelt as the majority shareholder.
NEW YORK , Dec. 6, 2024 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm by ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Arcadia Biosciences, Inc. (NASDAQ: RKDA ), relating to the proposed merger with Roosevelt Resources LP.
NEW YORK , Dec. 6, 2024 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Arcadia Biosciences, Inc. (NASDAQ: RKDA) and its board of directors concerning the proposed acquisition of the company by Roosevelt Resources LP. Arcadia stockholders will own approximately 10% of the combined company.
MILWAUKEE--(BUSINESS WIRE)--Ademi LLP is investigating Arcadia (NASDAQ: RKDA) for possible breaches of fiduciary duty and other violations of law in its transaction with Roosevelt Resources. Click here to learn how to join our investigation and obtain additional information or contact us at [email protected] or toll-free: 866-264-3995. There is no cost or obligation to you. Following the closing of the transaction, the current equity owners of Roosevelt Resources and the Arcadia shareholders.
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Arcadia Biosciences, Inc. (NASDAQ: RKDA) and Roosevelt Resources LP is fair to Arcadia shareholders. Upon closing of the proposed transaction, Arcadia shareholders are expected to own approximately 10% of the combined company. Halper Sadeh encourages Arcadia shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212.
DALLAS--(BUSINESS WIRE)--Arcadia Biosciences, Inc.® (Nasdaq: RKDA) and Roosevelt Resources LP announced today that they have entered into a definitive securities exchange agreement which, when completed, will combine the two companies in an all-stock transaction. Under the terms of the agreement, Arcadia will issue to the partners of Roosevelt shares of Arcadia common stock at the closing of the transaction in exchange for all of the equity interests in Roosevelt. Following the closing of the t.
RKDA witnesses a solid 55% improvement in Zola sales in Q3. The company continues to invest to grow the Zola brand.
Arcadia Biosciences (RKDA) came out with a quarterly loss of $0.87 per share versus the Zacks Consensus Estimate of a loss of $0.77. This compares to loss of $1.83 per share a year ago.
Arcadia Biosciences, Inc. (NASDAQ:RKDA ) Q3 2024 Earnings Conference Call November 12, 2024 4:30 PM ET Company Participants Mark Kawakami - Chief Financial Officer T.J. Schaefer - President & Chief Executive Officer Conference Call Participants Ben Klieve - Lake Street Capital Markets Operator Good afternoon, and welcome to Arcadia Biosciences Third Quarter 2024 Financial Results and Business Highlights Conference Call.
Arcadia Biosciences (RKDA) witnesses a solid 42% improvement in Zola sales in Q2. The company continues to invest to grow the Zola brand through mass market retailers and grocery store chains.